Original Query: ALL
Previous Study | Return to List | Next Study

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00071838
Recruitment Status : Completed
First Posted : November 3, 2003
Last Update Posted : July 2, 2017
Information provided by:
National Institutes of Health Clinical Center (CC)